Igenica Garners $33,000,000 Series C Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=218ffdfd-975b-4337-8cd2-87511125dc70&Preview=1
Date
6/12/2012
Company Name
Igenica
Mailing Address
863 Mitten Road Burlingame, CA 94010
Company Description
Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer.
Website
http://www.igenica.com
Transaction Type
Venture Equity
Transaction Amount
$33,000,000
Transaction Round
Series C
Proceeds Purposes
Proceeds from the financing will be used to advance the company’s monoclonal antibody pipeline toward clinical trials. These funds will also be used to apply Igenica’s unique discovery approach, consisting of the sTAg target discovery platform and the iTAb antibody discovery platform, toward the discovery of new monoclonal antibodies against a broad range of drug targets that have not been previously investigated for the treatment of cancer.
M&A Terms
Venture Investor
Third Rock Ventures
Venture Investor
The Column Group
Venture Investor
5AM Ventures
Venture Investor
OrbiMed Advisors